Date:2/9/2010

- $1,942 Cost of Products Sold 1,013 - - 1,013 ----- --- --- ----- Gross Margin 929 - - 929 Selling, General and Administrative Expenses 602 - (29) 573 Research and Development Expenses 73 - - 73 Restructuring and Acquisition Integration Charges 10 - (10) - --- --- --- --- Operating Income 244 - 39 283 Interest Expense and Other, Net 66 - (22) 44 --- --- --- --- Income Before Income Taxes 178 - 61 239 Provision for Income Taxes 50 - 15 65 --- --- --- --- Income from Continuing Operations 128 - 46 174 Income from Discontinued Operations, Net of Tax 23 (23) - - --- --- --- --- Net Income $151 $(23) $46 $174 ==== ==== === ==== Per Share Amounts:(4) Basic Earnings per Common Share $0.69 $(0.11) $0.21 $0.79 Diluted Earnings per Common Share $0.68 $(0.11) $0.21 $0.79 Weighted-Average Number of Common Shares Outstanding: Basic 220.7 220.7 220.7 220.7 Diluted 221.7 221.7 221.7 221.7 Effective Tax Rate 28.3% n/a 24.6% 27.2% (1) Reflects impact of
'/>"/>

SOURCE CareFusion Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine technology :

1. CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition
2. CareFusion Earns Top Ranking in MD Buyline and KLAS Reports
3. CareFusion Will Host An Earnings Conference Call on November 10, 2009 to Discuss the Results for the First Quarter of Fiscal 2010
4. CareFusion Shipping Ventilators to CDC for National Emergency Preparedness
5. CareFusion Moves First Quarter Earnings Announcement to November 5
6. CareFusion Announces 5-Year, Sole Source Pyxis(R) Perioperative Solutions Agreement With CHRISTUS Health
7. CareFusion Reports First Quarter Results, Raises Full-Year Outlook
8. CareFusion Signs Exclusive Partnership Agreement With Minimally Invasive Devices to Distribute FloShield Laparoscopic Technology
9. CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM)
10. CareFusion Will Host an Earnings Conference Call on Feb. 9 to Discuss the Results for the Second Quarter of Fiscal 2010
11. FDA Lifts Injunction on Manufacture and Sale of CareFusion Alaris(R) SE Pump